US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
META
$728.08
▲+0.00%
NVDA
$233.95
▲+0.00%
TSLA
$370.59
▲+0.00%
AMD
$633.91
▲+0.00%
JNJ
$256.03
▲+0.00%
SPCX
$158.96
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
META
$728.08
▲+0.00%
NVDA
$233.95
▲+0.00%
TSLA
$370.59
▲+0.00%
AMD
$633.91
▲+0.00%
JNJ
$256.03
▲+0.00%
SPCX
$158.96
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Zymeworks Inc. - Common Stock
(NQ:
ZYME
)
25.15
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Zymeworks Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
September 18, 2024
Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks’ proprietary antibody-drug conjugate development platforms
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)
September 03, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
August 22, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Navigating 6 Analyst Ratings For Zymeworks
↗
June 06, 2024
Via
Benzinga
Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock
August 01, 2024
Zymeworks intends to commence the Share Repurchase Program with $30.0 million in initial repurchases anticipated to begin promptly and continue during the second half of 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results
August 01, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
July 30, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
July 25, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
July 22, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
July 11, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
June 17, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare
↗
June 15, 2024
Shionogi, an Osaka innovative pharma, has signed an option agreement with Cilcare of France to in-license two drug candidates aimed at hearing loss in a deal worth up to $445 million. Meanwhile, XtalPi...
Via
Talk Markets
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
June 10, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
